Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Elastic NV (ESTC) vs Novartis AG (NVS) Price & Performance

Elastic NVTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Elastic NV vs Novartis AG — how do they compare? Elastic NV trades at $61.95 (market cap $6.47B), while Novartis AG trades at $151.94 (market cap $287.66B). The key difference: Novartis AG is far larger — about 44.5× Elastic NV's market cap, and Novartis AG pays a 3.14% dividend while Elastic NV pays none. Which is the better fit depends on your goals.

ESTCNVS
Market Cap
$6.47B$287.66B
Sector
TechnologyHealth
52-Week High
$94.47$168.62
52-Week Low
$43.30$113.50
Enterprise Value
$5.69B$327.68B
Dividend Yield
3.14%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Elastic NV

Elastic N.V. (ESTC) trades at $61.75, down 0.91% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust revenue growth, reaching $1.48B in 2025 with expectations of $1.7B in 2026, and has consistently beaten EPS estimates in recent quarters. Recent positive news includes Elastic Security achieving a 100% malware protection score and being named a Leader in IDC MarketScape's SIEM 2026 assessment.

Wall Street maintains a bullish outlook with 23 buy ratings and a $73 consensus price target, representing 18% upside. However, investors should note the high EV/EBITDA ratio of 164.13 and ongoing legal investigations highlighted in recent news. The stock's current RSI levels suggest potential overbought conditions, while strong profitability metrics and institutional support provide fundamental backing.

Novartis AG

Novartis (NVS) trades at $150.36, down 1.96% with bearish technical signals. The company maintains strong profitability with 75.38% gross margins and 23.92% net income margin, though recent earnings show mixed results with one beat and two misses. Recent acquisitions including Myricx Bio for up to $1.5 billion expand the oncology pipeline, while regulatory approvals for Itvisma and positive drug trial data support growth prospects.

While analyst consensus leans cautious with 68% hold ratings, Novartis' robust cash flow generation and strategic pipeline investments provide long-term value. Key risks include execution challenges from recent acquisitions and competitive pressures in pharmaceuticals. The stock offers stability through strong fundamentals but faces near-term technical headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Elastic NV

Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.

Read more on ESTC

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS